 |
Mar. 14, 2023 - Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
Read
Mar. 2, 2023 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
Feb. 28, 2023 - Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
Read
Feb. 16, 2023 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
Read
Feb. 1, 2023 - Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
Read
Jan. 12, 2023 - Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
Read
Jan. 9, 2023 - Puma Biotechnology Releases Updated Corporate Presentation
Read
Dec. 7, 2022 - Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
Read
Nov. 3, 2022 - Puma Biotechnology Reports Third Quarter 2022 Financial Results
- Raises FY 2022 NERLYNX Net Product Revenue Guidance
Read
Oct. 27, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Read
Oct. 20, 2022 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
Sept. 20, 2022 - Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
Read
Sept. 11, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
Read
Sept. 6, 2022 - Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Read
|
|
Upcoming Events
Past Events
Mar. 7, 2023 - Cowen’s 43rd Annual Health Care Conference
More
Mar. 2, 2023 - Puma Biotechnology 4Q-2022 Financial Results Conference Call
More
Jan. 19, 2023 - B. Riley Securities’ 3rd Annual Oncology Conference
More
Dec. 6 - 10, 2022 - San Antonio Breast Cancer Symposium
More
Nov. 3, 2022 - Puma Biotechnology 3Q-2022 Financial Results Conference Call
More
Oct. 27, 2022 - EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
More
Sept. 20, 2022 - Puma License Agreement for Alisertib
More
Sept. 12, 2022 - H.C. Wainwright 24th Annual Global Investment Conference
More
Sept. 11, 2022 - European Society for Medical Oncology (ESMO) Congress 2022
More
|
Annual Report Archives
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com
Business Development:
info@pumabiotechnology.com
Investor Relations:
ir@pumabiotechnology.com
Follow Us:
|
